Antipsychotic "Black Box" Warning Will Caution Against Off-Label Use In Dementia

FDA is requesting class labeling describing clinical trial results that show a higher rate of mortality in patients treated with atypical antipsychotics for dementia-related behavioral disorders compared to placebo. FDA's public health advisory and physician alert affect seven products.